Identification of a novel antitumor peptide based on the screening of an Ala‐library derived from the LALF32–51 region
- 11 November 2009
- journal article
- research article
- Published by Wiley in Journal of Peptide Science
- Vol. 16 (1) , 40-47
Abstract
Novel therapeutic peptides are increasingly making their way into clinical application. The cationic and amphipathic properties of certain peptides allow them to cross biological membranes in a non‐disruptive way without apparent toxicity increasing drug bioavailability. By modifying the primary structure of the Limulus‐derived LALF32–51 peptide we designed a novel peptide, L‐2, with antineoplastic effect and cell‐penetrating capacity. Interestingly, L‐2 induced cellular cytotoxicity in a variety of tumor cell lines and systemic injection into immunocompetent and nude mice bearing established solid tumor, resulted in substantial regression of the tumor mass and apoptosis. To isolate the gene transcripts specifically regulated by L‐2 in tumor cells, we conducted suppressive subtractive hybridization (SSH) analysis and identified a set of genes involved in biological processes relevant to cancer biology. Our findings describe a novel peptide that modifies the gene expression of the tumor cells and exhibits antitumor effect in vivo, indicating that peptide L‐2 is a potential candidate for anticancer therapy. Copyright © 2009 European Peptide Society and John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Nanostructure Formation Enhances the Activity of LPS‐Neutralizing PeptidesChemMedChem, 2008
- Bioactive peptides derived from the Limulus anti‐lipopolysaccharide factor: structure‐activity relationships and formation of mixed peptide/lipid complexesJournal of Peptide Science, 2008
- Studies on anticancer activities of antimicrobial peptidesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008
- Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification methodProteomics – Clinical Applications, 2007
- Blocking Platelet-Derived Growth Factor-D/Platelet-Derived Growth Factor Receptor β Signaling Inhibits Human Renal Cell Carcinoma Progression in an Orthotopic Mouse ModelCancer Research, 2005
- Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancerAdvanced Drug Delivery Reviews, 2005
- Identification of single amino acid residues essential for the binding of lipopolysaccharide (LPS) to LPS binding protein (LBP) residues 86–99 by using an Ala‐scanning libraryJournal of Peptide Science, 2002
- Arginine-rich PeptidesJournal of Biological Chemistry, 2001
- The BPI/LBP family of proteins: A structural analysis of conserved regionsProtein Science, 1998
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990